<DOC>
	<DOCNO>NCT00504959</DOCNO>
	<brief_summary>This extension study investigate long-term safety tolerability multiple intravitreal injection ranibizumab administer patient subfoveal choroidal neovascularization secondary age-related macular degeneration previously treat either two ongoing ranibizumab study CRFB002A2302 ( EXCITE ) CRFB002A2303 ( SUSTAIN</brief_summary>
	<brief_title>Safety Tolerability Ranibizumab Patients With Subfoveal Choroidal Neovascularization Secondary Age-related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Completion 12month treatment period study CRFB002A2302 ( EXCITE ) CRFB002A2303 Concurrent participation another clinical trial , i.e . use investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Age-related macular degeneration ( AMD ) ,</keyword>
	<keyword>choroidal neovascularization ( CNV ) ,</keyword>
	<keyword>vascular endothelial growth factor ( VEGF )</keyword>
</DOC>